Genmab A/S (GMAB) Q4 2022 Earnings Call Transcript

For the period ending December 31, 2022

February 22, 2023 12:00 p.m. ET

Prepared Remarks

Questions and Answers

Call Participants

Prepared Remarks:

Operator

Hello, and welcome to the Genmab Full-year 2022 Conference Call. As a reminder, this conference call is being recorded. During this telephone conference, you may be presented with forward-looking statements that include words such as believes, anticipates, plans or expects. Actual results may differ materially, for example, as a result of delays or unsuccessful development projects.

Genmab is not under any obligation to update statements regarding the future nor to confirm such statements in relation to actual results unless this is required by law. Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our privacy policy.

I would now like to hand the conference over to your first speaker today, Jan van de Winkel. Please go ahead.

Jan van de Winkel

Hello, and welcome to Genmab’s conference call to discuss the Company’s financial results for the period ending December 31, 2022. With me today to present these results is our CFO, Anthony Pagano. For the Q&A, we will be joined by our Chief Development Officer, Judith Klimovsky; our Chief Operating Officer, Anthony Mancini; and our Chief Medical Officer, Tahamtan Ahmadi.

Let’s move to Slide 2. As already said, we will be making forward-looking statements so please keep that in mind as we go through this call.

Let’s move to Slide 3. Genmab has a science-anchored and innovation-based culture and collaborations and partnerships have always been part of our DNA. During today’s presentation, we will reference products being developed under the strategic collaborations and this slide acknowledges those relationships.

Let’s move to Slide 4. Genmab has had transformative growth in all areas of our organization as we transitioned into an integrated biotech that brings our own medicines to patients. Certain fundamental aspects of our business, however, will remain unchanged. And these include innovative sciences that are core, and we strive to be forward thinking in all areas of our business.

And we have an unstoppable team that aspires to use our innovations in antibody therapeutics to fundamentally transform the lives of patients. These foundational pillars led to great progress last year, setting us on the path that inspired our 2030 vision, which we unveiled in 2022.